Medicus, Vol. 31 No. 2 Osteoporoza, 2022.
Pregledni rad
Teriparatide – A Valuable Osteoanabolic – What Do We Know So Far?
Jasminka Milas-Ahić
Sažetak
Teriparatide is the first anabolic drug approved for the treatment of osteoporosis. Its effectiveness in increasing bone mass and reducing the risk of osteoporotic fractures has been confirmed in daily clinical practice over the past 20 years. Teriparatide increases bone mineral density (BMD) and bone strength, and effectively reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. In addition to its efficacy in treating severe osteoporosis in postmenopausal women, teriparatide increases BMD and improves bone architecture in men with osteoporosis, as well as in patients with glucocorticoid-induced osteoporosis. Randomized clinical trials demonstrate the superiority of teriparatide compared to oral bisphosphonates in reducing vertebral fractures in postmenopausal osteoporosis, which was confirmed in a large number and different groups of patients in routine clinical practice. The use of teriparatide is currently limited to 24 months due to an indication of osteosarcoma development in rats in preclinical trials. However, post-marketing monitoring over a fifteen-year period did not show an increased risk of osteosarcoma in patients treated with teriparatide compared to the general population. The arrival of teriparatide biosimilars reduced treatment costs and increased availability to a larger number of patients; therefore, the recommendation of teriparatide as a potent anabolic drug could be extended to the treatment of severe osteoporosis as well.
Ključne riječi
teriparatide; osteoporosis; treatment; fractures
Hrčak ID:
291565
URI
Datum izdavanja:
17.1.2023.
Posjeta: 1.231 *